Antibody Production in Plants and Green Algae

Annual Review of Plant Biology

Volumn 67, Issue , 2016, Pages 669-701

  Yusibov, Vidadi ^a   Kushnir, Natasha ^a   Streatfield, Stephen J ^a  

^a Fraunhofer USA Inc   (United States)

Author keywords

Algae production; Glycoengineering; Monoclonal antibody; Plant production; Transgenic; Transient expression; Transplastomic

Indexed keywords

MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL; ANTIBODY PRODUCTION; BIOSYNTHESIS; GENETIC ENGINEERING; GENETICS; GREEN ALGA; METABOLISM; PLANT; TRANSGENIC PLANT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; CHLOROPHYTA; GENETIC ENGINEERING; PLANTS; PLANTS, GENETICALLY MODIFIED; RECOMBINANT PROTEINS;

EID: 84968860830     PISSN: 15435008     EISSN: 15452123     Source Type: Book Series    
DOI: 10.1146/annurev-arplant-043015-111812     Document Type: Review

References (208)

1. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. 2012. scFv antibody: principles and clinical application. Clin. Dev. Immunol. 2012:980250
2. Ahmadzadeh V, Farajnia S, Feizi MA,Nejad RA. 2014. Antibody humanizationmethods for development of therapeutic applications. Monoclon. Antib. Immunodiagn. Immunother. 33:67-73
3. Almquist KC, McLean MD, Niu Y, Byrne G, Olea-Popelka FC, et al. 2006. Expression of an antibotulinum toxin A neutralizing single-chain Fv recombinant antibody in transgenic tobacco. Vaccine 24:2079-86
4. Area Dev. News Desk. 2014. Kentucky Bioprocessing in Owensboro, Kentucky, producing delivery of breakthrough Ebola vaccine. Area Development, Oct. 16. http://www.areadevelopment.com/ newsItems/10-16-2014/kentucky-bioprocessing-breakthrough-ebola-therapy-owensborokentucky178233. shtml
5. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, et al. 2001. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059-70
6. Bakker H, Rouwendal GJ, Karnoup AS, Florack DE, Stoopen GM, et al. 2006. An antibody produced in tobacco expressing a hybrid -1,4-galactosyltransferase is essentially devoid of plant carbohydrate epitopes. PNAS 103:7577-82
7. Balali-Mood M, Moshiri M, Etemad L. 2013. Medical aspects of bio-terrorism. Toxicon 69:131-42
8. Barbosa O, Ortiz C, Berenguer-Murcia A, Torres R, Rodrigues RC, Fernandez-Lafuente R. 2015. Strategies for the one-step immobilization-purification of enzymes as industrial biocatalysts. Biotechnol. Adv. 33:435-56
9. Barrera DJ, Rosenberg JN, Chiu JG, Chang YN, Debatis M, et al. 2015. Algal chloroplast produced camelid VHHantitoxins are capable of neutralizing botulinum neurotoxin. Plant Biotechnol. J. 13:117-24
10. Basaran P, Rodriguez-Cerezo E. 2008. Plant molecular farming: opportunities and challenges. Crit. Rev. Biotechnol. 28:153-72
11. Bendandi M. 2008. Aiming at a curative strategy for follicular lymphoma. CA Cancer J. Clin. 58:305-17
12. Bendandi M. 2009. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat. Rev. Cancer 9:675-81
13. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, et al. 1999. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5:1171-77
14. Bendandi M, Marillonnet S, Kandzia R, Thieme F, Nickstadt A, et al. 2010. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann. Oncol. 21:2420-27
15. Benvenuto E, Ordas RJ, Tavazza R, Ancora G, Biocca S, et al. 1991. "Phytoantibodies": a general vector for the expression of immunoglobulin domains in transgenic plants. Plant Mol. Biol. 17:865-74
16. Berman D, Korman A, Peck R, Feltquate D, Lonberg N, Canetta R. 2015. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience. Pharmacol. Ther. 148:132-53
17. Biolex Ther. 2012. Biolex sells LEX System to Synthon and initiates sale of Locteron R- . Press Release, May 7, Biolex Ther., Pittsboro, NC. http://www.marketwired.com/press-release/biolex-sells-lexsystem-to-synthon-and-initiates-sale-of-locteron-1653466.htm
18. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, et al. 2002. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287:2391-405
19. Bosch D, Castilho A, Loos A, Schots A, Steinkellner H. 2013. N-glycosylation of plant-produced recombinant proteins. Curr. Pharm. Des. 19:5503-12
20. Brachman PS, Kaufmann A. 1998. Anthrax. In Bacterial Infections of Humans, ed. P Brachman, AS Evans, pp. 95-111. New York: Plenum
21. Brachman PS, Plotkin SA, Bumford FH, Atchison MM. 1960. An epidemic of inhalation anthrax: The first in the twentieth century. II. Epidemiology. Am. J. Hyg. 72:6-23
22. Breiman A, Fawcett TW, Ghirardi ML, Mattoo AK. 1992. Plant organelles contain distinct peptidylprolyl cis,trans-isomerases. J. Biol. Chem. 267:21293-96
23. Bronte G, Sortino G, Passiglia F, Rizzo S, Lo Vullo F, et al. 2015. Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. Expert Opin. Biol. Ther. 15:45-59
24. Burnouf T, Radosevich M. 2001. Affinity chromatography in the industrial purification of plasma proteins for therapeutic use. J. Biochem. Biophys. Methods 49:575-86
25. Castilho A, Gattinger P, Grass J, Jez J, Pabst M, et al. 2011. N-glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and branched complex N-glycans. Glycobiology 21:813-23
26. Castilho A, Neumann L, Daskalova S, Mason HS, Steinkellner H, et al. 2012. Engineering of sialylated mucin-type O-glycosylation in plants. J. Biol. Chem. 287:36518-26
27. Castilho A, Strasser R, Stadlmann J, Grass J, Jez J, et al. 2010. In planta protein sialylation through overexpression of the respective mammalian pathway. J. Biol. Chem. 285:15923-30
28. Celik E, Calik P. 2012. Production of recombinant proteins by yeast cells. Biotechnol. Adv. 30:1108-18
29. Cent. Dis. Control Prev. 2013. Facts about ricin. http://www.bt.cdc.gov/agent/ricin/facts.asp
30. Cent. Dis. Control Prev. 2015. Ebola (Ebola virus disease). http://www.cdc.gov/vhf/ebola
31. Cent. Dis. Control Prev. 2015. General questions about West Nile virus. http://www.cdc.gov/westnile/ faq/genquestions.html
32. Cent. Dis. Control Prev. 2015. Outbreaks chronology: Ebola virus disease. http://www.cdc.gov/vhf/ ebola/outbreaks/history/chronology.html
33. Chargelegue D, Drake PM, Obregon P, Prada A, Fairweather N, Ma JK. 2005. Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plants. Infect. Immun. 73:5915-22
34. Chen R. 2012. Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnol. Adv. 30:1102-7
35. ClinicalTrials.gov. 2011. A safety study of a single vaginal administration of P2G12 antibody in healthy female subjects. Stud. Rec. NCT01403792, Natl. Inst. Health, Bethesda,MD. https://clinicaltrials.gov/ ct2/show/NCT01403792
36. ClinicalTrials.gov. 2015. Putative investigational therapeutics in the treatment of patients with known Ebola infection. Stud. Rec. NCT02363322, Natl. Inst. Health, Bethesda,MD. https://clinicaltrials.gov/ ct2/show/NCT02363322
37. ClinicalTrials.gov. 2015. Safety and pharmacokinetics of a single ZMappTM administration in healthy adult volunteers. Stud. Rec. NCT02389192, Natl. Inst. Health, Bethesda, MD. https://clinicaltrials.gov/ ct2/show/NCT02389192
38. Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, et al. 2006. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat. Biotechnol. 24:1591-97
39. Daniell H, Singh ND, Mason H, Streatfield SJ. 2009. Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci. 14:669-79
40. Danielli R, Patuzzo R, Ruffini PA, Maurichi A, Giovannoni L, et al. 2015. Armed antibodies for cancer treatment: a promising tool in a changing era. Cancer Immunol. Immunother. 64:113-21
41. Danon A,Mayfield SP. 1994. Light-regulated translation of chloroplastmessenger RNAs through redox potential. Science 266:1717-19
42. Daskalova SM, Radder JE, Cichacz ZA, Olsen SH, Tsaprailis G, et al. 2010. Engineering of N. benthamiana L. plants for production of N-acetylgalactosamine-glycosylated proteins-towards development of a plant-based platform for production of protein therapeutics with mucin type O-glycosylation. BMC Biotechnol. 10:62
43. Davies JC. 1982. A major epidemic of anthrax in Zimbabwe. Cent. Afr. J. Med. 28:291-98
44. De Muynck B, Navarre C, Boutry M. 2010. Production of antibodies in plants: status after twenty years. Plant Biotechnol. J. 8:529-63
45. De Neve M, De Loose M, Jacobs A, Van Houdt H, Kaluza B, et al. 1993. Assembly of an antibody and its derived antibody fragment in Nicotiana and Arabidopsis. Transgenic Res. 2:227-37
46. Defyrus. 2015. Ebola-ZMAb. http://www.defyrus.com/products-ebola-zmab.html
47. Dolk E, van Vliet C, Perez JM, Vriend G, Darbon H, et al. 2005. Induced refolding of a temperature denatured llama heavy-chain antibody fragment by its antigen. Proteins 59:555-64
48. Drugmand JC, Schneider YJ, Agathos SN. 2012. Insect cells as factories for biomanufacturing. Biotechnol. Adv. 30:1140-57
49. Ecker DM, Jones SD, Levine HL. 2015. The therapeutic monoclonal antibody market. mAbs 7:9-14
50. Ellis RW, Gerety RJ. 1990. Key issues in the selection of an expression system for vaccine antigens. J. Med. Virol. 31:54-58
51. Engelman A, Cherepanov P. 2012.Thestructural biology of HIV-1: mechanistic and therapeutic insights. Nat. Rev. Microbiol. 10:279-90
52. Falsey AR,Walsh EE. 2000. Respiratory syncytial virus infection in adults. Clin.Microbiol. Rev. 13:371-84
53. Farajnia S, Ahmadzadeh V, Tanomand A, Veisi K, Khosroshahi SA, Rahbarnia L. 2014. Development trends for generation of single-chain antibody fragments. Immunopharmacol. Immunotoxicol. 36:297-308
54. Fowler K, McBride BW, Turnbull PC, Baillie LW. 1999. Immune correlates of protection against anthrax. J. Appl. Microbiol. 87:305
55. Frieden TR, Damon I, Bell BP, Kenyon T, Nichol S. 2014. Ebola 2014-new challenges, new global response and responsibility. N. Engl. J. Med. 371:1177-80
56. Gallie DR, Kado CI. 1989. A translational enhancer derived from tobacco mosaic virus is functionally equivalent to a Shine-Dalgarno sequence. PNAS 86:129-32
57. Gasdaska JR, Sherwood S, Regan JT, Dickey LF. 2012. An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complementdependent cytotoxicity than rituximab. Mol. Immunol. 50:134-41
58. Giritch A, Marillonnet S, Engler C, van Eldik G, Botterman J, et al. 2006. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. PNAS 103:14701-6
59. Gleba Y, Klimyuk V, Marillonnet S. 2005. Magnifection-a new platform for expressing recombinant vaccines in plants. Vaccine 23:2042-48
60. GlennieMJ, French RR, CraggMS, Taylor RP. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44:3823-37
61. Gomord V, Faye L. 2004. Posttranslational modification of therapeutic proteins in plants. Curr. Opin. Plant Biol. 7:171-81
62. GomordV, Fitchette AC,Menu-BouaouicheL, Saint-Jore-DupasC,PlassonC, et al. 2010. Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotechnol. J. 8:564-87
63. Grogan TM, Jaramillo M. 2002. Pathology of non-Hodgkin's lymphoma. In Malignant Lymphomas, ed. M Grossbard, pp. 1-30. Madrid: BC Decker
64. He J, LaiH, Engle M, Gorlatov S, Gruber C, et al. 2014. Generation and analysis of novel plant-derived antibody-based therapeutic molecules against West Nile virus. PLOS ONE 9:e93541
65. Hein MB, Tang Y, McLeod DA, Janda KD, Hiatt A. 1991. Evaluation of immunoglobulins from plant cells. Biotechnol. Prog. 7:455-61
66. Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C. 2007. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J. Immunol. 178:2361-69
67. Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, et al. 2014. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. PNAS 111:5992-97
68. Hiatt A, Cafferkey R, Bowdish K. 1989. Production of antibodies in transgenic plants. Nature 342:76-78
69. Huang Z, PhoolcharoenW, Lai H, Piensook K, Cardineau G, et al. 2010. High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system. Biotechnol. Bioeng. 106:9-17
70. Hull AK, Criscuolo CJ, Mett V, Groen H, Steeman W, et al. 2005. Human-derived, plant-produced monoclonal antibody for the treatment of anthrax. Vaccine 23:2082-86
71. IMpact-RSV Stud. Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531-37
72. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. 1999. Anthrax as a biological weapon: medical and public health management. JAMA 281:1735-45
73. Jacobs PP, Callewaert N. 2009. N-glycosylation engineering of biopharmaceutical expression systems. Curr. Mol. Med. 9:774-800
74. Jahn T, Zuther M, Friedrichs B, Heuser C, Guhlke S, et al. 2012. An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack. PLOS ONE 7:e44482
75. Jefferis R. 2005. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 21:11-16
76. Jefferis R. 2012. Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 526:159-66
77. Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, et al. 2001. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerg. Infect. Dis. 7:933-44
78. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. 1999. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 104:419-27
79. Kishore U, Reid KB. 2000. C1q: structure, function, and receptors. Immunopharmacology 49:159-70
80. Koch R. 1877. The aetiology of anthrax based on the ontogeny of the anthrax bacillus. Beitr. Biol. Pflanz. 2:277-82
81. Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-97
82. Kramer K, Hock B. 2003. Recombinant antibodies for environmental analysis. Anal. Bioanal. Chem. 377:417-26
83. Kuroki M, Shirasu N. 2014. Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens. Anticancer Res. 34:4481-88
84. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. 1992. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327:1209-15
85. Lai H, Engle M, Fuchs A, Keller T, Johnson S, et al. 2010. Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. PNAS 107:2419-24
86. Lai H, He J, Engle M, Diamond MS, Chen Q. 2012. Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce. Plant Biotechnol. J. 10:95-104
87. Lai H, He J, Hurtado J, Stahnke J, Fuchs A, et al. 2014. Structural and functional characterization of an anti-West Nile virus monoclonal antibody and its single-chain variant produced in glycoengineered plants. Plant Biotechnol. J. 12:1098-107
88. Lameris R, de Bruin RC, Schneiders FL, van Bergen en Henegouwen PM, Verheul HM, et al. 2014. Bispecific antibody platforms for cancer immunotherapy. Crit. Rev. Oncol. Hematol. 92:153-65
89. Landry N, Ward BJ, Trepanier S, Montomoli E, DargisM, et al. 2010. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLOS ONE 5:e15559
90. Larrick JW, Yu L, Naftzger C, Jaiswal S, Wycoff K. 2001. Production of secretory IgA antibodies in plants. Biomol. Eng. 18:87-94
91. Leader S, Kohlhase K. 2003. Recent trends in severe respiratory syncytial virus (RSV) amongUS infants, 1997 to 2000. J. Pediatr. 143:S127-32
92. Lee JE, FuscoML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. 2008. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454:177-82
93. Levs J, Wilson J. 2014. 'Miraculous day' as American Ebola patients released. CNN, Aug. 22. http:// edition.cnn.com/2014/08/21/health/ebola-patient-release
94. Lico C, Santi L, Twyman RM, Pezzotti M, Avesani L. 2012. The use of plants for the production of therapeutic human peptides. Plant Cell Rep. 31:439-51
95. Little SF, Ivins BE, Fellows PF, Friedlander AM. 1997. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65:5171-75
96. Little SF, Ivins BE, Fellows PF, PittML, Norris SL, AndrewsGP. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22:422-30
97. Loos A, Gruber C, Altmann F, Mehofer U, Hensel F, et al. 2014. Expression and glycoengineering of functionally active heteromultimeric IgM in plants. PNAS 111:6263-68
98. Loos A, Steinkellner H. 2012. IgG-Fc glycoengineering in non-mammalian expression hosts. Arch. Biochem. Biophys. 526:167-73
99. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, et al. 2014. Clinical care of two patients with Ebola virus disease in the United States. N. Engl. J. Med. 371:2402-9
100. Ma JK, Drossard J, Lewis D, Altmann F, Boyle J, et al. 2015. Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. Plant Biotechnol. J. 13:1106-20
101. Ma JK,Hiatt A,HeinM, VineND, Wang F, et al. 1995. Generation and assembly of secretory antibodies in plants. Science 268:716-19
102. Ma JK,Hikmat BY, Wycoff K, VineND, ChargelegueD, et al. 1998. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat. Med. 4:601-6
103. Ma JK, Lehner T, Stabila P, Fux CI, Hiatt A. 1994. Assembly of monoclonal antibodies with IgG1 and IgA heavy chain domains in transgenic tobacco plants. Eur. J. Immunol. 24:131-38
104. Mamedov T, Ghosh A, Jones RM,Mett V, Farrance CE, et al. 2012. Production of non-glycosylated recombinant proteins in Nicotiana benthamiana plants by co-expressing bacterial PNGase F. Plant Biotechnol. J. 10:773-82
105. Mapp Biopharm. 2015. Product development: our product pipeline. http://www.mappbio.com/productdevelopment
106. Mapp Biopharm. 2015. ZMappTM. http://mappbio.com/z-mapp
107. Marillonnet S, Giritch A, Gils M, Kandzia R, Klimyuk V, Gleba Y. 2004. In planta engineering of viral RNA replicons: efficient assembly by recombination ofDNA modules delivered by Agrobacterium. PNAS 101:6852-57
108. Marsden CJ, Eckersley S, Hebditch M, Kvist AJ, Milner R, et al. 2014. The use of antibodies in smallmolecule drug discovery. J. Biomol. Screen. 19:829-38
109. Marusic C, Novelli F, Salzano AM, Scaloni A, Benvenuto E, et al. 2016. Production of an active anti-CD20-hIL-2 immunocytokine in Nicotiana benthamiana. Plant Biotechnol. J. 14:240-51
110. Matzke MA,Mette MF,Matzke AJ. 2000. Transgene silencing by the host genome defense: implications for the evolution of epigenetic control mechanisms in plants and vertebrates. Plant Mol. Biol. 43:401-15
111. Mayfield SP, Franklin SE, Lerner RA. 2003. Expression and assembly of a fully active antibody in algae. PNAS 100:438-42
112. McCarthyM. 2014. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 349:g5488
113. McCormick AA, Kumagai MH, Hanley K, Turpen TH, Hakim I, et al. 1999. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. PNAS 96:703-8
114. McCormick AA, Reddy S, Reinl SJ, Cameron TI, Czerwinkski DK, et al. 2008. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. PNAS 105:10131-36
115. McCormick AA, Reinl SJ, Cameron TI, Vojdani F, FronefieldM, et al. 2003. Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. J. Immunol. Methods 278:95-104
116. Medicago. 2015. Medicago awarded a contract by the U.S. Department of Health and Human Services to explore alternate production methods for Ebola antibodies. Press Release, Feb. 24, Medicago, Quebec, Can. http://www.medicago.com/files/documents-news/2015/Ebola-PR-USA-English-Final-v001- j1v036.pdf
117. Mett V, Chichester JA, StewartML, MusiychukK, BiH, et al. 2011. A non-glycosylated, plant-produced human monoclonal antibody against anthrax protective antigen protects mice and non-human primates from B. anthracis spore challenge. Hum. Vaccines 7(Suppl.):183-90
118. Modjtahedi H, Ali S, Essapen S. 2012. Therapeutic application of monoclonal antibodies in cancer: advances and challenges. Br. Med. Bull. 104:41-59
119. Montecucco C, Molgo J. 2005. Botulinal neurotoxins: revival of an old killer. Curr. Opin. Pharmacol. 5:274-79
120. Moore C. 2014. Texas biotech firm affirms readiness to produce commercial quantities of anti-Ebola vaccines and biotherapeutics quickly and cost-effectively if asked. BioNews Texas, Aug. 8. http:// bionews-tx.com/news/2014/08/08/texas-biotech-firm-affirms-readiness-produce-commercialquantities-anti-ebola-vaccines-biotherapeutics-quickly-cost-effectively-asked
121. Morris GC, Wiggins RC, Woodhall SC, Bland JM, Taylor CR, et al. 2014. MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide. PLOS ONE 9:e116153
122. Naidoo J, Page DB,Wolchok JD. 2014. Immune modulation for cancer therapy. Br. J. Cancer 111:2214-19
123. Nicolas E, Beggs JM, Haltiwanger BM, Taraschi TF. 1997. Direct evidence for the deoxyribonuclease activity of the plant ribosome inactivating protein gelonin. FEBS Lett. 406:162-64
124. O'Hara JM, Whaley K, Pauly M, Zeitlin L, Mantis NJ. 2012. Plant-based expression of a partially humanized neutralizing monoclonal IgG directed against an immunodominant epitope on the ricin toxin A subunit. Vaccine 30:1239-43
125. Olinger GG Jr, Pettitt J, Kim D, Working C, Bohorov O, et al. 2012. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. PNAS 109:18030-35
126. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, et al. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522-30
127. Owen M, Gandecha A, Cockburn B, Whitelam G. 1992. Synthesis of a functional anti-phytochrome single-chain Fv protein in transgenic tobacco. Biotechnology 10:790-94
128. Palacpac NQ, Yoshida S, Sakai H, Kimura Y, Fujiyama K, et al. 1999. Stable expression of human 1,4-galactosyltransferase in plant cells modifies N-linked glycosylation patterns. PNAS 96:4692-97
129. Paul M, Reljic R, Klein K, DrakePM, vanDolleweerdC, et al. 2014. Characterization of a plant-produced recombinant human secretory IgA with broad neutralizing activity against HIV. mAbs 6:1585-97
130. Pettitt J, Zeitlin L, Kim DH, Working C, Johnson JC, et al. 2013. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med. 5:199ra13
131. PhoolcharoenW, Bhoo SH, Lai H,Ma J, Arntzen CJ, et al. 2011. Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. Plant Biotechnol. J. 9:807-16
132. Phoolcharoen W, Dye JM, Kilbourne J, Piensook K, Pratt WD, et al. 2011. A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. PNAS 108:20695-700
133. Pirie CM, Hackel BJ, Rosenblum MG,Wittrup KD. 2011. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J. Biol. Chem. 286:4165-72
134. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, et al. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-73
135. Plosker GL, Figgitt DP. 2003. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63:803-43
136. Prigent J, Panigai L, Lamourette P, Sauvaire D, Devilliers K, et al. 2011. Neutralising antibodies against ricin toxin. PLOS ONE 6:e20166
137. Pujol M, Ramirez NI, Ayala M, Gavilondo JV, Valdes R, et al. 2005. An integral approach towards a practical application for a plant-made monoclonal antibody in vaccine purification. Vaccine 23:1833-37
138. Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, et al. 2000. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19:142-53
139. Qiu X, Alimonti JB, Melito PL, Fernando L, Stroher U, Jones SM. 2011. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin. Immunol. 141:218-27
140. Qiu X, Audet J, Wong G, Pillet S, Bello A, et al. 2012. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4:138ra81
141. Qiu X, Wong G, Audet J, Bello A, Fernando L, et al. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47-53
142. Rademacher T, Sack M, Arcalis E, Stadlmann J, Balzer S, et al. 2008. Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. Plant Biotechnol. J. 6:189-201
143. Ramessar K, Rademacher T, Sack M, Stadlmann J, Platis D, et al. 2008. Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. PNAS 105:3727-32
144. Rasala BA, Mayfield SP. 2015. Photosynthetic biomanufacturing in green algae; production of recombinant proteins for industrial, nutritional, and medical uses. Photosynth. Res. 123:227-39
145. Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, et al. 2006. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J. Clin. Oncol. 24:3107-12
146. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, et al. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-45
147. Reichert JM. 2015. Antibodies to watch in 2015. mAbs 7:1-8
148. Robinette RA, Oli MW, McArthur WP, Brady LJ. 2011. A therapeutic anti-Streptococcus mutans monoclonal antibody used in human passive protection trials influences the adaptive immune response. Vaccine 29:6292-300
149. Rosenberg JN, Oyler GA, Wilkinson L, Betenbaugh MJ. 2008. A green light for engineered algae: redirecting metabolism to fuel a biotechnology revolution. Curr. Opin. Biotechnol. 19:430-36
150. Rosenberg Y, Sack M, Montefiori D, Forthal D, Mao L, et al. 2013. Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. PLOS ONE 8:e58724
151. Rouwendal GJ, Wuhrer M, Florack DE, Koeleman CA, Deelder AM, et al. 2007. Efficient introduction of a bisecting GlcNAc residue in tobacco N-glycans by expression of the gene encoding human N-acetylglucosaminyltransferase III. Glycobiology 17:334-44
152. Roy CJ, Brey RN, Mantis NJ,Mapes K, Pop IV, et al. 2015. Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: epitope-specific neutralizing antibodies correlate with protection. PNAS 112:3782-87
153. Rybicki EP. 2010. Plant-made vaccines for humans and animals. Plant Biotechnol. J. 8:620-37
154. Rybicki EP. 2014. Plant-based vaccines against viruses. Virol. J. 11:205
155. SaerensD,GhassabehGH, Muyldermans S. 2008. Single-domain antibodies as building blocks for novel therapeutics. Curr. Opin. Pharmacol. 8:600-8
156. Sainsbury F, Ca ñizares MC, Lomonossoff GP. 2010. Cowpea mosaic virus: The plant virus-based biotechnology workhorse. Annu. Rev. Phytopathol. 48:437-55
157. Sainsbury F, Sack M, Stadlmann J, Quendler H, Fischer R, Lomonossoff GP. 2010. Rapid transient production in plants by replicating and non-replicating vectors yields high quality functional anti-HIV antibody. PLOS ONE 5:e13976
158. Sapra P, Shor B. 2013. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol. Ther. 138:452-69
159. Schahs M, Strasser R, Stadlmann J, Kunert R, Rademacher T, Steinkellner H. 2007. Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotechnol. J. 5:657-63
160. Schouten A, Roosien J, van Engelen FA, de Jong GA, Borst-Vrenssen AW, et al. 1996. The C-terminal KDEL sequence increases the expression level of a single-chain antibody designed to be targeted to both the cytosol and the secretory pathway in transgenic tobacco. Plant Mol. Biol. 30:781-93
161. Schroda M. 2004. The Chlamydomonas genome reveals its secrets: chaperone genes and the potential roles of their gene products in the chloroplast. Photosynth. Res. 82:221-40
162. Senyuva HZ, Gilbert J. 2010. Immunoaffinity column clean-up techniques in food analysis: a review. J. Chromatogr. B 878:115-32
163. Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, et al. 2007. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol. J. 5:579-90
164. Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, Bates P. 2002. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 76:2518-28
165. Smallshaw JE, Richardson JA, Vitetta ES. 2007. RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. Vaccine 25:7459-69
166. Smith R, Lehner T. 1989. Characterisation of monoclonal antibodies to common protein epitopes on the cell surface of Streptococcus mutans and Streptococcus sobrinus. Oral Microbiol. Immunol. 4:153-58
167. Stoger E, Fischer R, Moloney M, Ma JK. 2014. Plant molecular pharming for the treatment of chronic and infectious diseases. Annu. Rev. Plant Biol. 65:743-68
168. Strasser R, Altmann F, Mach L, Glossl J, Steinkellner H. 2004. Generation of Arabidopsis thaliana plants with complex N-glycans lacking 1,2-linked xylose and core 1,3-linked fucose. FEBS Lett. 561:132-36
169. Strasser R, Castilho A, Stadlmann J, Kunert R, Quendler H, et al. 2009. Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous 1,4-galactosylated N-glycan profile. J. Biol. Chem. 284:20479-85
170. Strasser R, Stadlmann J, Schahs M, Stiegler G, Quendler H, et al. 2008. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 6:392-402
171. Thakur MS, Ragavan KV. 2013. Biosensors in food processing. J. Food Sci. Technol. 50:625-41
172. Tiwari S, Verma PC, Singh PK, Tuli R. 2009. Plants as bioreactors for the production of vaccine antigens. Biotechnol. Adv. 27:449-67
173. Tran M, Henry RE, Siefker D, Van C, Newkirk G, et al. 2013. Production of anti-cancer immunotoxins in algae: ribosome inactivating proteins as fusion partners. Biotechnol. Bioeng. 110:2826-35
174. Tran M, Van C, Barrera DJ, Pettersson PL, PeinadoCD, et al. 2013. Production of unique immunotoxin cancer therapeutics in algal chloroplasts. PNAS 110:E15-22
175. Tran M, Zhou B, Pettersson PL, GonzalezMJ, Mayfield SP. 2009. Synthesis and assembly of a full-length human monoclonal antibody in algal chloroplasts. Biotechnol. Bioeng. 104:663-73
176. Traynor K. 2012. Taliglucerase alfa approved for Gaucher disease. Am. J. Health Syst. Pharm. 69:1009
177. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-8
178. Tsirigotis P, Economopoulos T. 2008. Monoclonal antibodies in the treatment of lymphoid malignancies. J. Steroid Biochem. Mol. Biol. 108:267-71
179. Tusé D, Ku N, Bendandi M, Becerra C, Collins R Jr, et al. 2015. Clinical safety and immunogenicity of tumor-targeted, plant-made Id-KLH conjugate vaccines for follicular lymphoma. BioMed. Res. Int. 2015:648143
180. Ugwu CU, Aoyagi H, Uchiyama H. 2008. Photobioreactors for mass cultivation of algae. Bioresour. Technol. 99:4021-28
181. US Food Drug Admin. 2013. FDA approves first Botulism Antitoxin for use in neutralizing all seven known botulinum nerve toxin serotypes. News Release, Mar. 22, US Food Drug Admin., Washington, DC. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345128.htm
182. Valdes R, Reyes B, Alvarez T, Garcia J, Montero JA, et al. 2003. Hepatitis B surface antigen immunopurification using a plant-derived specific antibody produced in large scale. Biochem. Biophys. Res. Commun. 310:742-47
183. van der Linden RH, Frenken LG, de Geus B, Harmsen MM, Ruuls RC, et al. 1999. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim. Biophys. Acta 1431:37-46
184. Van Ness GB. 1971. Ecology of anthrax. Science 172:1303-7
185. Verma D, Daniell H. 2007. Chloroplast vector systems for biotechnology applications. Plant Physiol. 145:1129-43
186. Ward BJ, Landry N, Trepanier S, Mercier G, Dargis M, et al. 2014. Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. Vaccine 32:6098-106
187. Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I. 2014. Immunotoxins for leukemia. Blood 123:2470-77
188. Weber DJ, Rutala WA. 2001. Risks and prevention of nosocomial transmission of rare zoonotic diseases. Clin. Infect. Dis. 32:446-56
189. Webster DE, Thomas MC. 2012. Post-translational modification of plant-made foreign proteins; glycosylation and beyond. Biotechnol. Adv. 30:410-18
190. Weintraub JA, Hilton JF,White JM,Hoover CI,Wycoff KL, et al. 2005. Clinical trial of a plant-derived antibody on recolonization of mutans streptococci. Caries Res. 39:241-50
191. Weiss S, Kobiler D, Levy H, Marcus H, Pass A, et al. 2006. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect. Immun. 74:394-98
192. Whaley KJ, Morton J, Hume S, Hiatt E, Bratcher B, et al. 2014. Emerging antibody-based products. Curr. Top. Microbiol. Immunol. 375:107-26
193. WHO (World Health Organ.). 2013. Botulism. Fact Sheet 270, WHO, Geneva, Switz. http://www. who.int/mediacentre/factsheets/fs270
194. WHO(WorldHealthOrgan.). 2014. Ebola response roadmap situation report. Rep., WHO, Geneva, Switz. http://apps.who.int/iris/bitstream/10665/146763/1/roadmapsitrep-31Dec14-eng.pdf
195. WHO (World Health Organ.). 2015. Ebola data and statistics. WHO, Geneva, Switz. http://apps. who.int/gho/data/view.ebola-sitrep.ebola-summary-20150112
196. WHO (World Health Organ.). 2015. HIV/AIDS. Fact Sheet 360, WHO, Geneva, Switz. http://www. who.int/mediacentre/factsheets/fs360
197. WHO Ebola Response Team. 2014. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N. Engl. J. Med. 371:1481-95
198. Wilson JA, Hevey M, Bakken R, Guest S, Bray M, et al. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287:1664-66
199. Xu J, Dolan MC, Medrano G, Cramer CL,Weathers PJ. 2012. Green factory: plants as bioproduction platforms for recombinant proteins. Biotechnol. Adv. 30:1171-84
200. Yang Z, Drew DP, Jorgensen B, Mandel U, Bach SS, et al. 2012. Engineering mammalian mucin-type O-glycosylation in plants. J. Biol. Chem. 287:11911-23
201. Young JA, CollierRJ. 2007. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 76:243-65
202. Yusibov V, KushnirN, Streatfield SJ. 2015. Advances and challenges in the development and production of effective plant-based influenza vaccines. Expert Rev. Vaccines 14:519-35
203. Yusibov V, Streatfield SJ, Kushnir N. 2011. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum. Vaccines 7:313-21
204. Yusibov V, Streatfield SJ, Kushnir N, Roy G, Padmanaban A. 2013. Hybrid viral vectors for vaccine and antibody production in plants. Curr. Pharm. Des. 19:5574-86
205. Zeitlin L, Bohorov O, Bohorova N, Hiatt A, Kim DH, et al. 2013. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. mAbs 5:263-69
206. Zeitlin L, Pettitt J, Scully C, Bohorova N, Kim D, et al. 2011. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. PNAS 108:20690-94
207. Zhang X, Soori G, Dobleman TJ, Xiao GG. 2014. The application of monoclonal antibodies in cancer diagnosis. Expert Rev. Mol. Diagn. 14:97-106
208. Zhu J. 2012. Mammalian cell protein expression for biopharmaceutical production. Biotechnol. Adv. 30:1158-70